Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Rockville, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Cutaneous T-cell lymphoma diagnosis market is estimated to ...

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 1% on Wednesday. Following the ...